Clinical Trial Update: Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating regorafenib plus a PD-1 antibody with radiotherapy for metastatic colorectal cancer that is microsatellite stable (MSS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)
• Regorafenib (regorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer Metastatic, MSS | Phase 2 | Status: UNKNOWN